0001006281 2015-01-01 2015-09-30 0001006281 2015-09-30 0001006281 2014-12-31 0001006281 2014-01-01 2014-09-30 0001006281 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-09-30 0001006281 us-gaap:ResearchAndDevelopmentExpenseMember 2014-01-01 2014-09-30 0001006281 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-01-01 2015-09-30 0001006281 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2014-01-01 2014-09-30 0001006281 2013-12-31 0001006281 2014-09-30 0001006281 us-gaap:CommonStockMember 2013-12-31 0001006281 us-gaap:AdditionalPaidInCapitalMember 2013-12-31 0001006281 us-gaap:RetainedEarningsMember 2013-12-31 0001006281 us-gaap:AdditionalPaidInCapitalMember 2014-01-01 2014-09-30 0001006281 us-gaap:CommonStockMember 2014-01-01 2014-09-30 0001006281 us-gaap:RetainedEarningsMember 2014-01-01 2014-09-30 0001006281 us-gaap:CommonStockMember 2014-09-30 0001006281 us-gaap:AdditionalPaidInCapitalMember 2014-09-30 0001006281 us-gaap:RetainedEarningsMember 2014-09-30 0001006281 us-gaap:CommonStockMember 2014-12-31 0001006281 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0001006281 us-gaap:RetainedEarningsMember 2014-12-31 0001006281 us-gaap:CommonStockMember 2015-01-01 2015-09-30 0001006281 us-gaap:AdditionalPaidInCapitalMember 2015-01-01 2015-09-30 0001006281 us-gaap:RetainedEarningsMember 2015-01-01 2015-09-30 0001006281 us-gaap:CommonStockMember 2015-09-30 0001006281 us-gaap:AdditionalPaidInCapitalMember 2015-09-30 0001006281 us-gaap:RetainedEarningsMember 2015-09-30 0001006281 us-gaap:SubsidiariesMember plx:BrazilAgreementMember plx:FiocruzMember 2015-01-01 2015-09-30 0001006281 us-gaap:SubsidiariesMember plx:BrazilAgreementMember plx:FiocruzMember 2013-06-18 0001006281 plx:ProtalixBioTherapeuticsIncorporationMember plx:PfizerAgreementMember 2015-09-30 0001006281 plx:PfizerIncorporationMember plx:PfizerAgreementMember 2015-09-30 0001006281 2014-07-01 2014-09-30 0001006281 2015-07-01 2015-09-30 0001006281 us-gaap:ResearchAndDevelopmentExpenseMember 2015-07-01 2015-09-30 0001006281 us-gaap:ResearchAndDevelopmentExpenseMember 2014-07-01 2014-09-30 0001006281 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-07-01 2015-09-30 0001006281 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2014-07-01 2014-09-30 0001006281 us-gaap:EmployeeStockOptionMember plx:EmployeeStockIncentivePlan2006Member 2015-03-23 0001006281 us-gaap:EmployeeStockOptionMember plx:EmployeeStockIncentivePlan2006Member 2015-03-01 2015-03-23 0001006281 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheOneMember plx:EmployeeStockIncentivePlan2006Member 2015-03-01 2015-03-23 0001006281 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember plx:EmployeeStockIncentivePlan2006Member 2015-03-01 2015-03-23 0001006281 2015-11-01 0001006281 us-gaap:SubsequentEventMember plx:AmendedPfizerAgreementMember country:BR plx:ProtalixBioTherapeuticsIncorporationMember 2015-10-31 0001006281 plx:AmendedPfizerAgreementMember plx:PfizerIncorporationMember us-gaap:SubsequentEventMember plx:ExcludingBrazilMember 2015-10-31 0001006281 us-gaap:SubsequentEventMember plx:AmendedPfizerAgreementMember 2015-10-01 2015-10-31 0001006281 plx:ProtalixBioTherapeuticsIncorporationMember us-gaap:SubsequentEventMember plx:AmendedPfizerAgreementMember 2015-10-31 0001006281 us-gaap:SubsequentEventMember plx:PfizerIncorporationMember 2015-10-01 2015-10-31 0001006281 us-gaap:SubsequentEventMember us-gaap:ExecutiveOfficerMember 2015-10-01 2015-10-31 0001006281 us-gaap:SubsequentEventMember 2015-10-01 2015-10-31 0001006281 plx:AmendedPfizerAgreementMember plx:October2015PromissoryNoteToPfizerMember us-gaap:SubsequentEventMember 2015-10-31 0001006281 plx:AmendedPfizerAgreementMember plx:October2015PromissoryNoteToPfizerMember us-gaap:SubsequentEventMember 2015-10-01 2015-10-31 iso4217:USD iso4217:USD xbrli:shares xbrli:shares xbrli:pure plx:item 6667000 47876000 65520000 1569000 1555000 9957000 11282000 90000 113000 59492000 78470000 4057000 3951000 11946000 15496000 6850000 6763000 22853000 26210000 67774000 34248000 67464000 35127000 37232000 912000 2249000 2253000 105150000 107861000 128003000 134071000 54767000 -68511000 -55601000 59492000 78470000 4573000 1884000 2716000 2202000 6339000 -14863000 -21474000 1419000 683000 1811000 2418000 -102000 -869000 16000 149000 -28000 25000 333000 332000 -2018000 -6172000 3187000 578000 -328000 -1127000 -4396000 -1736000 -20427000 -24407000 460000 617000 93000 122000 -516000 -832000 534000 43000 534000 43000 -110000 -885000 -20519000 -26081000 86398000 60317000 146000 122000 3105000 3079000 56000 94000 184345000 -211385000 -26946000 161000 161000 522000 522000 113800 43000 43000 -21474000 93663064 94000 185071000 -232859000 -47694000 93603819 94000 185633000 -241328000 947000 947000 2501 -2501 472000 472000 -14863000 94151318 94000 187586000 -256191000 0.001 150000000 93551098 550000 534000 534000 0.001 150000000 12475000 11517000 3084000 2259000 6785000 7476000 8774000 6300000 18493000 23280000 3856000 6146000 14637000 17134000 6259000 7289000 -12122000 -18123000 2805000 3490000 64000 139000 -2741000 -3351000 -0.16 -0.23 93599414 92828851 667000 764000 752000 -81000 1909000 5260000 8052000 1207000 1947000 4053000 6105000 2254000 2012000 -2807000 -6208000 1030000 1851000 17000 49000 -1013000 -1802000 -3820000 -8010000 -0.04 -0.09 93943772 92971572 258000 173000 188000 -67000 4301000 2396000 1545000 1311000 2346000 1798000 3500000 Accelerated Filer Q3 2015 0001006281 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"><b>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES</b></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">&#160;</p> <div> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; margin-top: 0px; margin-bottom: 0px;"> <tr style="vertical-align: top; text-align: justify;"> <td style="width: 0.5in;"></td> <td style="width: 0.25in; text-align: left;"><b>a.</b></td> <td style="text-align: justify;"><b>General</b></td> </tr> </table> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 0pt; margin-bottom: 0pt; font-stretch: normal;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"><font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#147;Company&#148;), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company's proprietary ProCellEx&#174; protein expression system (&#147;ProCellEx&#148;). Using the ProCellEx system, the Company is developing a pipeline of proprietary recombinant therapeutic proteins. The Company's initial commercial focus has been on complex therapeutic proteins, including proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. The Company's strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. To date, the Company has successfully developed a treatment for Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets, and the Company has number of product candidates in varying stages of the clinical development process. In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency (&#147;EMA&#148;) application process in the European Union. The Company's two subsidiaries are referred to collectively herein as the &#147;Subsidiaries.&#148;</font></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">On May 1, 2012, the U.S. Food and Drug Administration (&#147;FDA&#148;) approved for sale the Company's first commercial product, taliglucerase alfa for injection, an enzyme replacement therapy (&#147;ERT&#148;) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Subsequently, taliglucerase alfa was approved for marketing by the regulatory authorities of other countries. Taliglucerase alfa is being marketed under the name Uplyso^TM in Brazil and certain other Latin American countries and&#160;Elelyso^TM in the rest of the territories.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">Since its approval by the FDA, taliglucerase alfa has been marketed mainly in the United States by Pfizer Inc. (&#147;Pfizer&#148;), the Company's commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd., the Company's wholly-owned subsidiary, and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, the Company entered into an Amended and Restated Exclusive License and Supply Agreement (the &#147;Amended Pfizer Agreement&#148;) which amends and restates the Pfizer Agreement in its entirety. Pursuant to the Amended Pfizer Agreement, the Company sold to Pfizer its share in the collaboration created under the initial Pfizer Agreement for the commercialization of Elelyso in exchange for a cash payment equal to $<font>36.0</font> million. <font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to Elelyso in Brazil. Under the initial Pfizer Agreement, Pfizer and the Company shared revenues and expenses for the development and commercialization of Elelyso on a&#160;</font><font>60</font>%/<font>40</font>% basis globally, excluding Israel and Brazil. Under the Amended Pfizer Agreement, Pfizer is responsible for <font>100</font>% of expenses, and entitled to all of the revenues, globally for Elelyso, excluding Brazil, where the Company is responsible for all expenses and retains all revenues. The Amended Pfizer Agreement eliminates Pfizer's entitlement to annual payments of up to $<font>12.5</font> million in relation to commercialization of Elelyso in Brazil.&#160;<font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">For further details please see Note 5.</font></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">On June 18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#147;Brazil Agreement&#148;) with Funda&#231;&#227;o Oswaldo Cruz (&#147;Fiocruz&#148;), an arm of the Brazilian Ministry of Health for taliglucerase alfa. The agreement became effective in January 2014. The technology transfer is designed to be completed in <font>four</font> stages and is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high-quality, and cost-effective supply of taliglucerase alfa. The Company is not required to complete the final stage of the technology transfer until Fiocruz purchases at least approximately $<font>280</font> million worth of taliglucerase alfa.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"><font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">Fiocruz's purchases of Uplyso to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the low purchase amounts, the Company is, at this time, continuing to supply Uplyso to Fiocruz under the Brazil Agreement, and patients continue to be treated with Uplyso in Brazil. Approximately</font>&#160;<font>10</font>% of adult Gaucher patients in Brazil are currently treated with Uplyso. The Company is discussing with Fiocruz potential actions that Fiocruz may take to comply with its purchase obligations and, based on such discussions, the Company will determine what it believes to be the course of action that is in the best interest of the Company.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">The Company will pay a fee equal to <font>5</font>%&#160;<font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">of the net proceeds generated in Brazil to an agent for services provided in assisting the Company complete the Brazil Agreement pursuant to an agreement between the agent and the Company. The agreement will remain in effect with respect to the Brazil Agreement until the termination thereof.</font></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">In addition to taliglucerase alfa, the Company is developing an innovative product pipeline using its ProCellEx protein expression system. The Company's product pipeline currently includes, among other candidates:</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">(1) PRX-102, or alpha-GAL-A, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder in humans.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">(2) PRX-106, the Company's oral antiTNF product candidate which is being developed as an orally-delivered anti inflammatory treatment using plant cells as a natural capsule for the expressed protein.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">(3) PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, under development for the treatment of cystic fibrosis, to be administered by inhalation.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">(4) PRX-112, an orally administered glucocerebrosidase enzyme for the treatment of Gaucher patients utilizing oral delivery of the recombinant GCD enzyme produced and encapsulated within carrot cells.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"><br/></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">Obtaining marketing approval with respect to any product candidate in any country is directly dependent on the Company's ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for <font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">at least 12 months</font>, although <font>no</font> assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing.</p> </div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>&#160;</b></font></p> <div> <div class="CursorPointer"> <table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;"> <tr style="vertical-align: top;"> <td style="width: 0.5in;"></td> <td style="width: 0.25in; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>b.</b></font></td> <td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>Basis of Presentation</b></font></td> </tr> </table> </div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#147;GAAP&#148;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2014, filed by the Company with the U.S. Securities and Exchange Commission <font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">(the &#147;Commission&#148;)</font>. The comparative balance sheet at December 31, 2014 has been derived from the audited financial statements at that date.</font></p> </div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>&#160;</b></font></p> <div> <div class="CursorPointer"> <table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;"> <tr style="vertical-align: top;"> <td style="width: 0.5in;"></td> <td style="width: 0.25in; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>c.</b></font></td> <td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>Net loss per share</b></font></td> </tr> </table> </div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Basic and diluted loss per share (&#147;LPS&#148;) are computed by dividing net loss by the weighted average number of shares of the Company's common stock, par value $<font>0.001</font> per share (the &#147;Common Stock&#148;) outstanding for each period. Diluted LPS does not include <font>18,781,572</font>&#160;and <font>19,797,190</font> shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of the convertible notes (issued in September 2013) for the nine months ended September 30, 2014 and 2015, respectively, and <font>18,661,182</font> and <font>19,820,485</font> shares of Common Stock for the three months ended September 30, 2014 and 2015, respectively, because the effect would be anti-dilutive.</font></p> </div> </div> <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div class="CursorPointer"> <table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;"> <tr style="vertical-align: top;"> <td style="width: 0.5in;"></td> <td style="width: 0.25in; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>b.</b></font></td> <td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>Basis of Presentation</b></font></td> </tr> </table> </div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#147;GAAP&#148;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2014, filed by the Company with the U.S. Securities and Exchange Commission <font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">(the &#147;Commission&#148;)</font>. The comparative balance sheet at December 31, 2014 has been derived from the audited financial statements at that date.</font></p> </div> 99800397 -1834 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div class="CursorPointer"> <table cellpadding="0" cellspacing="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-top: 0px; margin-bottom: 0px; width: 100%;"> <tr style="vertical-align: top;"> <td style="width: 0.5in;"></td> <td style="width: 0.25in; font-family: 'times new roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>c.</b></font></td> <td style="font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>Net loss per share</b></font></td> </tr> </table> </div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Basic and diluted loss per share (&#147;LPS&#148;) are computed by dividing net loss by the weighted average number of shares of the Company's common stock, par value $<font>0.001</font> per share (the &#147;Common Stock&#148;) outstanding for each period. Diluted LPS does not include <font>18,781,572</font>&#160;and <font>19,797,190</font> shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of the convertible notes (issued in September 2013) for the nine months ended September 30, 2014 and 2015, respectively, and <font>18,661,182</font> and <font>19,820,485</font> shares of Common Stock for the three months ended September 30, 2014 and 2015, respectively, because the effect would be anti-dilutive.</font></p> </div> 18781572 19797190 18661182 19820485 1502000 1616000 132000 4837000 4919000 1600000 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-family: 'times new roman', times; font-size: 10pt;"><b>NOTE 2 - INVENTORIES</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"><font style="font-family: 'times new roman', times; font-size: 10pt;">Inventory at September 30, 2015 and December 31, 2014 consisted of the following:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></p> <div> <div style="display: block; margin-left: 0.7in;"> <div class="CursorPointer"> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 85%; /* margin-left: 0.7in;"> <tr style="vertical-align: bottom;"> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.75pt solid;"><strong><font style="font-family: 'times new roman', times; font-size: 10pt;"> September 30, </font></strong></p> </td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><strong><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></strong></td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap" colspan="2"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.75pt solid;"><strong><font style="font-family: 'times new roman', times; font-size: 10pt;"> December 31, </font></strong></p> </td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px; width: 20px;" nowrap="nowrap" colspan="5"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><br/></p> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.75pt solid;"><strong><font style="font-family: 'times new roman', times; font-size: 10pt;"> 2015 </font></strong></p> </td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><strong><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></strong></td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap" colspan="2"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.75pt solid;"><strong><font style="font-family: 'times new roman', times; font-size: 10pt;"> 2014 </font></strong></p> </td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px; width: 20px;" nowrap="nowrap" colspan="5"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><br/></p> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: 'Times New Roman';" nowrap="nowrap"></td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"></td> <td style="text-align: center; padding: 0px;" colspan="6" nowrap="nowrap"><font style="font-family: 'times new roman', times; font-size: 10pt;">(<i>U.S. dollars in thousands)</i></font></td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"></td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 74%;"><font style="font-family: 'times new roman', times; font-size: 10pt;">Raw materials</font></td> <td style="font-family: 'times new roman'; padding: 0px; width: 1%;"></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;"><font style="font-family: 'times new roman', times; font-size: 10pt;">$</font></td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt;">1,502</font></font></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> <td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;"><font style="font-family: 'times new roman', times; font-size: 10pt;">$</font></td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font style="font-family: 'times new roman', times; font-size: 10pt;"><font>1,616</font></font></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">Work&#160;in&#160;progress</font></td> <td style="font-family: 'Times New Roman';"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><br/></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;"><font>132</font></font></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">Finished goods</font></td> <td style="font-family: 'times new roman'; padding: 0px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt;">4,837</font></font></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;"><font>4,919</font></font></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">Total inventory</font></td> <td style="font-family: 'times new roman'; padding: 0px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;">$</font></td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt;">6,339</font></font></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;">$</font></td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;"><font>6,667</font></font></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> </tr> </table> </div> </div> </div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.9pt;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"><font style="font-family: 'times new roman', times; font-size: 10pt;">During the nine months ended September 30, 2015, the Company recorded approximately $<font><strong><font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">1.6</font></strong></font>&#160;million for write-down of inventory under cost of revenues.</font></p> </div> 1834 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div style="display: block; margin-left: 0.7in;"> <div class="CursorPointer"> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 85%; /* margin-left: 0.7in;"> <tr style="vertical-align: bottom;"> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.75pt solid;"><strong><font style="font-family: 'times new roman', times; font-size: 10pt;"> September 30, </font></strong></p> </td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><strong><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></strong></td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap" colspan="2"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.75pt solid;"><strong><font style="font-family: 'times new roman', times; font-size: 10pt;"> December 31, </font></strong></p> </td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px; width: 20px;" nowrap="nowrap" colspan="5"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><br/></p> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.75pt solid;"><strong><font style="font-family: 'times new roman', times; font-size: 10pt;"> 2015 </font></strong></p> </td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><strong><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></strong></td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap" colspan="2"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.75pt solid;"><strong><font style="font-family: 'times new roman', times; font-size: 10pt;"> 2014 </font></strong></p> </td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px; width: 20px;" nowrap="nowrap" colspan="5"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><br/></p> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: 'Times New Roman';" nowrap="nowrap"></td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"></td> <td style="text-align: center; padding: 0px;" colspan="6" nowrap="nowrap"><font style="font-family: 'times new roman', times; font-size: 10pt;">(<i>U.S. dollars in thousands)</i></font></td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"></td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; width: 74%;"><font style="font-family: 'times new roman', times; font-size: 10pt;">Raw materials</font></td> <td style="font-family: 'times new roman'; padding: 0px; width: 1%;"></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;"><font style="font-family: 'times new roman', times; font-size: 10pt;">$</font></td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font><font style="font-size: 10pt;">1,502</font></font></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> <td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;"><font style="font-family: 'times new roman', times; font-size: 10pt;">$</font></td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 10%;"><font style="font-family: 'times new roman', times; font-size: 10pt;"><font>1,616</font></font></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">Work&#160;in&#160;progress</font></td> <td style="font-family: 'Times New Roman';"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><br/></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;"><font>132</font></font></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">Finished goods</font></td> <td style="font-family: 'times new roman'; padding: 0px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt;">4,837</font></font></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;"><font>4,919</font></font></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">Total inventory</font></td> <td style="font-family: 'times new roman'; padding: 0px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;">$</font></td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font><font style="font-size: 10pt;">6,339</font></font></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;">$</font></td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;"><font>6,667</font></font></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></td> </tr> </table> </div> </div> </div> 45500000 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt; font-family: 'times new roman', times;"><b>NOTE 3 &#150; FAIR VALUE MEASUREMENT</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in;"><font style="font-size: 10pt; font-family: 'times new roman', times;">The fair value of the convertible notes as of September 30, 2015 is approximately $<font>45.5</font>&#160;million based on a level 2 measurement.</font></p> </div> 1900000 0.00 0.617 0.016 P6Y <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-family: 'times new roman', times; font-size: 10pt;"><b>NOTE 4 &#150; STOCK TRANSACTIONS</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0in;"><font style="font-family: 'times new roman', times; font-size: 10pt;">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0in;"><font style="font-family: 'times new roman', times; font-size: 10pt;">On March 23, 2015, the Company's compensation committee approved the grant of a <font>10</font>-year option to purchase <font>1,909,000</font> shares of Common Stock to its officers and other employees with an exercise price equal to $<font>1.72</font> per share under the Company's 2006 Employee Stock Incentive Plan, as amended (the &#147;Plan&#148;). The options vest over a <font>four</font>-year period; the first <font>25</font>% shares vest on the first anniversary of the grant date and the remaining shares vest in <font>12</font> equal quarterly increments over the subsequent <font>three</font>-year period. Vesting of the options granted to certain executive officers are subject to acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $<font>1.9</font> million based on the following weighted average assumptions: dividend yield of <font>0</font>% for all years; expected volatility of <font>61.7</font>%; risk-free interest rates of <font>1.6</font>%; and expected life of <font>six</font> years.</font></p> </div> P10Y 1909000 1.72 P4Y 0.25 12 P3Y false --12-31 2015-09-30 PLX PROTALIX BIOTHERAPEUTICS, INC. 10-Q 12500000 280000000 0.60 0.40 0.10 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;"><b>NOTE 5 &#150; SUBSEQUENT EVENTS</b></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 0.5in;">On October 12, 2015, the Company entered into the Amended Pfizer Agreement which amends and restates, in its entirety, the Pfizer Agreement. See Note 1. Pursuant to the Amended Pfizer Agreement, the Company sold its share in the collaboration with Pfizer on the commercialization of Elelyso to Pfizer in exchange for a cash payment equal to $<font>36.0</font> million. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer in exchange for full rights to Elelyso in Brazil. Under the Amended Pfizer Agreement, the Company will continue to manufacture drug substance for Pfizer, subject to certain terms and conditions. In addition, the Company issued to Pfizer a promissory note for approximately $<font>4.2</font> million, representing the Company's share of accumulated losses as of the date of the Amended Pfizer Agreement.&#160;The note is to be paid in October 2020, subject to certain terms and conditions. Under the Pfizer Agreement, Pfizer and the Company shared in revenues and expenses for the development and commercialization of Elelyso on a 60%/40% basis globally, excluding Israel and Brazil. Under the Amended Pfizer Agreement, Pfizer is responsible for 100% of expenses, and entitled to all of the revenues, globally for Elelyso, excluding Brazil, where the Company is responsible for all expenses and retains all revenues. The Amended Pfizer Agreement eliminates Pfizer's entitlement to annual payments of up to $12.5 million in relation to commercialization of Elelyso in Brazil.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 0.5in;"><br/></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 0.5in;">On October 12, 2015, the Company also entered into a Stock Purchase Agreement with Pfizer, pursuant to which the Company issued <font>5,649,079</font> shares of the Company's common stock for an aggregate purchase price equal to $<font>10.0</font>&#160;million subject to certain other terms set forth in the Stock Purchase Agreement. As part of the Stock Purchase Agreement, Pfizer has agreed to a <font>180</font>-day lock-up with respect to the purchased shares and the Company's directors and executive officers have entered into <font>90</font>-day lock up agreements.</p> </div> 5649079 10000000 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: auto; text-indent: 0px; text-transform: none; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; margin-top: 0px; margin-bottom: 0px;"> <tr style="vertical-align: top; text-align: justify;"> <td style="width: 0.5in;"></td> <td style="width: 0.25in; text-align: left;"><b>a.</b></td> <td style="text-align: justify;"><b>General</b></td> </tr> </table> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 0pt; margin-bottom: 0pt; font-stretch: normal;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"><font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#147;Company&#148;), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company's proprietary ProCellEx&#174; protein expression system (&#147;ProCellEx&#148;). Using the ProCellEx system, the Company is developing a pipeline of proprietary recombinant therapeutic proteins. The Company's initial commercial focus has been on complex therapeutic proteins, including proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. The Company's strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. To date, the Company has successfully developed a treatment for Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets, and the Company has number of product candidates in varying stages of the clinical development process. In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency (&#147;EMA&#148;) application process in the European Union. The Company's two subsidiaries are referred to collectively herein as the &#147;Subsidiaries.&#148;</font></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">On May 1, 2012, the U.S. Food and Drug Administration (&#147;FDA&#148;) approved for sale the Company's first commercial product, taliglucerase alfa for injection, an enzyme replacement therapy (&#147;ERT&#148;) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Subsequently, taliglucerase alfa was approved for marketing by the regulatory authorities of other countries. Taliglucerase alfa is being marketed under the name Uplyso^TM in Brazil and certain other Latin American countries and&#160;Elelyso^TM in the rest of the territories.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">Since its approval by the FDA, taliglucerase alfa has been marketed mainly in the United States by Pfizer Inc. (&#147;Pfizer&#148;), the Company's commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd., the Company's wholly-owned subsidiary, and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, the Company entered into an Amended and Restated Exclusive License and Supply Agreement (the &#147;Amended Pfizer Agreement&#148;) which amends and restates the Pfizer Agreement in its entirety. Pursuant to the Amended Pfizer Agreement, the Company sold to Pfizer its share in the collaboration created under the initial Pfizer Agreement for the commercialization of Elelyso in exchange for a cash payment equal to $<font>36.0</font> million. <font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to Elelyso in Brazil. Under the initial Pfizer Agreement, Pfizer and the Company shared revenues and expenses for the development and commercialization of Elelyso on a&#160;</font><font>60</font>%/<font>40</font>% basis globally, excluding Israel and Brazil. Under the Amended Pfizer Agreement, Pfizer is responsible for <font>100</font>% of expenses, and entitled to all of the revenues, globally for Elelyso, excluding Brazil, where the Company is responsible for all expenses and retains all revenues. The Amended Pfizer Agreement eliminates Pfizer's entitlement to annual payments of up to $<font>12.5</font> million in relation to commercialization of Elelyso in Brazil.&#160;<font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">For further details please see Note 5.</font></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">On June 18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#147;Brazil Agreement&#148;) with Funda&#231;&#227;o Oswaldo Cruz (&#147;Fiocruz&#148;), an arm of the Brazilian Ministry of Health for taliglucerase alfa. The agreement became effective in January 2014. The technology transfer is designed to be completed in <font>four</font> stages and is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high-quality, and cost-effective supply of taliglucerase alfa. The Company is not required to complete the final stage of the technology transfer until Fiocruz purchases at least approximately $<font>280</font> million worth of taliglucerase alfa.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"><font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">Fiocruz's purchases of Uplyso to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the low purchase amounts, the Company is, at this time, continuing to supply Uplyso to Fiocruz under the Brazil Agreement, and patients continue to be treated with Uplyso in Brazil. Approximately</font>&#160;<font>10</font>% of adult Gaucher patients in Brazil are currently treated with Uplyso. The Company is discussing with Fiocruz potential actions that Fiocruz may take to comply with its purchase obligations and, based on such discussions, the Company will determine what it believes to be the course of action that is in the best interest of the Company.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">The Company will pay a fee equal to <font>5</font>%&#160;<font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">of the net proceeds generated in Brazil to an agent for services provided in assisting the Company complete the Brazil Agreement pursuant to an agreement between the agent and the Company. The agreement will remain in effect with respect to the Brazil Agreement until the termination thereof.</font></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">In addition to taliglucerase alfa, the Company is developing an innovative product pipeline using its ProCellEx protein expression system. The Company's product pipeline currently includes, among other candidates:</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">(1) PRX-102, or alpha-GAL-A, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder in humans.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">(2) PRX-106, the Company's oral antiTNF product candidate which is being developed as an orally-delivered anti inflammatory treatment using plant cells as a natural capsule for the expressed protein.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">(3) PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, under development for the treatment of cystic fibrosis, to be administered by inhalation.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">(4) PRX-112, an orally administered glucocerebrosidase enzyme for the treatment of Gaucher patients utilizing oral delivery of the recombinant GCD enzyme produced and encapsulated within carrot cells.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;"><br/></p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">Obtaining marketing approval with respect to any product candidate in any country is directly dependent on the Company's ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">&#160;</p> <p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px 0pt 56.7pt;">Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for <font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">at least 12 months</font>, although <font>no</font> assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing.</p> </div> 36000000 1.00 1.00 0.05 P180D P90D 4200000 2020-10-31 Represents amount less than thousand